Curaleaf's $272M hostile bid for Aurora at 45% premium

Curaleaf Holdings plans to launch a $272 million hostile takeover of Aurora Cannabis, offering $4 per share — a 45 percent premium to the Canadian company's 30-day average — after its board repeatedly declined to engage in acquisition talks.

"We will now take our proposal directly to Aurora shareholders because the premium is significant, the strategic rationale is compelling, and further delay is unjustified," Boris Jordan, chairman and chief executive officer of Curaleaf, said in a statement.

The offer consists of 0.3463 Curaleaf shares and 75 cents in cash per Aurora share. Aurora stock jumped 20 percent to $3.45 on the Nasdaq, while Curaleaf rose 2.35 percent. Tilray Brands climbed nearly 4 percent to an intraday high of $4.70 as investors rotated into cannabis names on consolidation expectations, and the AdvisorShares Pure US Cannabis ETF gained more than 2 percent.

If completed, the combination would create a cannabis company operating in 17 countries with more than $1.5 billion in trailing 12-month revenue and a market capitalization approaching $3 billion. Curaleaf estimates at least $40 million in annual cost savings, with the deal expanding its international footprint through Aurora's medical cannabis franchise in Europe and Canada.

Curaleaf, valued at $2.2 billion, first approached Aurora privately in June, sending a formal letter of intent on June 23. It followed up on July 7 after Aurora declined to engage, but the Edmonton-based company remained "unwilling to engage in constructive discussions," according to Curaleaf. The bid has not been formally launched, and Curaleaf said there is no guarantee the offer will ultimately be made.

Aurora Board Rejects $4 Offer

TD Cowen analysts Derek Lessard and Ryan Neal pushed back on the offer's valuation, writing in a note that the proposed consideration "does not fully capture Aurora's long-term intrinsic value." They cited Aurora's market leadership in medical cannabis, strong balance sheet, and ability to navigate complex international regulatory requirements.

Aurora trades on both the Nasdaq and Toronto Stock Exchange. The company's stock had been trading near multi-year lows before the bid became public, making it an attractive target for consolidation. On the TSX, Aurora shares rose 20.84 percent to C$4.87.

Jordan said merging the companies would "unlock value" by combining Curaleaf's global distribution platform with Aurora's leading international medical cannabis franchise and its cultivation and manufacturing capacity. He said the deal represents "a win-win for Curaleaf and Aurora shareholders," offering Aurora investors "a unique opportunity to participate in a more highly diversified global platform."

DEA Rescheduling Deadline Looms Aug. 17

The hostile bid arrives as the U.S. cannabis industry awaits a key deadline in the federal rescheduling process. Participants in the Drug Enforcement Administration's rescheduling hearing must submit post-hearing briefs to the administrative law judge by Aug. 17, after which the judge will issue recommendations — a process that could take weeks or months.

The prospect of federal rescheduling has fueled M&A speculation across the sector, with investors betting that regulatory tailwinds will drive further consolidation. Jordan said the deal would give Aurora shareholders "increased exposure to U.S. regulatory tailwinds" through Curaleaf's domestic operations.

Tilray Brands, once among the largest cannabis companies, has diversified into beverages and international markets, with revenue rising 11 percent to $915 million in its last fiscal year. Its cannabis, beverage, distribution, and wellness segments generated $268 million, $254 million, $327 million, and $65 million, respectively. Some investors view Tilray as a potential acquisition target if sector consolidation accelerates.

If Curaleaf succeeds, the combined entity would rank among the largest cannabis companies globally, with a footprint spanning North America, Europe, and other international markets. The outcome now hinges on whether Aurora's shareholders accept the offer or push for a higher price, and on whether any competing bidders emerge as the sector consolidates.

This article is for informational purposes only and does not constitute investment advice.